Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hemophilia A | 9 | 2018 | 15 | 1.910 |
Why?
|
| Factor VIII | 6 | 2018 | 11 | 1.330 |
Why?
|
| Antibodies, Neutralizing | 4 | 2018 | 7 | 0.960 |
Why?
|
| Isoantibodies | 3 | 2018 | 3 | 0.920 |
Why?
|
| Mutation | 1 | 2018 | 77 | 0.530 |
Why?
|
| Coagulants | 2 | 2017 | 3 | 0.390 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 92 | 0.390 |
Why?
|
| Humans | 15 | 2018 | 2957 | 0.370 |
Why?
|
| Recombinant Proteins | 3 | 2017 | 57 | 0.330 |
Why?
|
| Male | 11 | 2018 | 1860 | 0.300 |
Why?
|
| Hemorrhage | 4 | 2017 | 9 | 0.290 |
Why?
|
| Child, Preschool | 6 | 2017 | 119 | 0.270 |
Why?
|
| Hemophilia B | 2 | 2017 | 3 | 0.260 |
Why?
|
| Factor VIIa | 2 | 2017 | 3 | 0.260 |
Why?
|
| Risk Assessment | 1 | 2017 | 51 | 0.260 |
Why?
|
| Time Factors | 3 | 2018 | 208 | 0.220 |
Why?
|
| Treatment Outcome | 3 | 2018 | 186 | 0.220 |
Why?
|
| Risk Factors | 2 | 2018 | 275 | 0.190 |
Why?
|
| Phenotype | 3 | 2018 | 75 | 0.180 |
Why?
|
| Young Adult | 6 | 2017 | 187 | 0.170 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 97 | 0.160 |
Why?
|
| Adolescent | 6 | 2017 | 247 | 0.160 |
Why?
|
| Hodgkin Disease | 1 | 2009 | 1 | 0.150 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2009 | 11 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 15 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 25 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 85 | 0.150 |
Why?
|
| Sickle Cell Trait | 1 | 2018 | 1 | 0.140 |
Why?
|
| Sports Medicine | 1 | 2018 | 1 | 0.140 |
Why?
|
| Television | 1 | 2018 | 1 | 0.140 |
Why?
|
| Information Dissemination | 1 | 2018 | 1 | 0.140 |
Why?
|
| Athletes | 1 | 2018 | 1 | 0.140 |
Why?
|
| Genetic Testing | 1 | 2018 | 17 | 0.140 |
Why?
|
| Asia | 1 | 2018 | 1 | 0.140 |
Why?
|
| South America | 1 | 2018 | 1 | 0.140 |
Why?
|
| North America | 1 | 2018 | 2 | 0.140 |
Why?
|
| Europe | 1 | 2018 | 3 | 0.140 |
Why?
|
| Africa | 1 | 2018 | 4 | 0.140 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 19 | 0.140 |
Why?
|
| Social Media | 1 | 2018 | 17 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2018 | 50 | 0.140 |
Why?
|
| Anticoagulants | 2 | 2015 | 16 | 0.140 |
Why?
|
| Adult | 5 | 2017 | 794 | 0.120 |
Why?
|
| von Willebrand Factor | 1 | 2016 | 2 | 0.120 |
Why?
|
| Hematology | 1 | 2016 | 2 | 0.120 |
Why?
|
| Career Choice | 1 | 2016 | 4 | 0.120 |
Why?
|
| Physicians, Women | 1 | 2016 | 5 | 0.120 |
Why?
|
| Leadership | 1 | 2016 | 21 | 0.120 |
Why?
|
| Infant | 3 | 2016 | 122 | 0.120 |
Why?
|
| Physician Executives | 1 | 2016 | 7 | 0.120 |
Why?
|
| Child | 4 | 2016 | 197 | 0.110 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 9 | 0.110 |
Why?
|
| Female | 5 | 2018 | 1724 | 0.110 |
Why?
|
| Middle Aged | 4 | 2017 | 792 | 0.110 |
Why?
|
| Factor VII Deficiency | 1 | 2013 | 1 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 85 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 51 | 0.090 |
Why?
|
| Joint Diseases | 1 | 2011 | 5 | 0.090 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2009 | 1 | 0.080 |
Why?
|
| Vena Cava, Inferior | 1 | 2009 | 2 | 0.080 |
Why?
|
| Death, Sudden | 1 | 2009 | 3 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2009 | 2 | 0.080 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 7 | 0.080 |
Why?
|
| Headache | 2 | 2017 | 8 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2017 | 7 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 50 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2017 | 11 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 14 | 0.060 |
Why?
|
| United States | 2 | 2018 | 243 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2016 | 233 | 0.060 |
Why?
|
| Hemarthrosis | 2 | 2017 | 8 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2017 | 203 | 0.050 |
Why?
|
| Aged | 2 | 2016 | 956 | 0.050 |
Why?
|
| Subtraction Technique | 1 | 2009 | 1 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2009 | 11 | 0.040 |
Why?
|
| Newspapers as Topic | 1 | 2018 | 1 | 0.040 |
Why?
|
| Metabolic Clearance Rate | 1 | 2017 | 2 | 0.030 |
Why?
|
| Dizziness | 1 | 2017 | 4 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2017 | 7 | 0.030 |
Why?
|
| Half-Life | 1 | 2016 | 1 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 2016 | 3 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 14 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 20 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 4 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 17 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 4 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 5 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 110 | 0.030 |
Why?
|
| Colorado | 1 | 2015 | 1 | 0.030 |
Why?
|
| Florida | 1 | 2015 | 1 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 2 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 8 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2015 | 13 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2015 | 19 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 12 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 6 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 12 | 0.030 |
Why?
|
| Research Design | 1 | 2015 | 21 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2015 | 47 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 83 | 0.030 |
Why?
|
| Fibrinolysis | 1 | 2013 | 1 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 105 | 0.020 |
Why?
|
| Synovitis | 1 | 2011 | 8 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 19 | 0.020 |
Why?
|
| Mice | 1 | 2011 | 343 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 2009 | 4 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 4 | 0.020 |
Why?
|
| Autopsy | 1 | 2009 | 39 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 1050 | 0.020 |
Why?
|